Evidence map›Paper›PMID 42156973›Full record

ReviewNature reviews. Neurology2026

Rethinking prognosis in multiple sclerosis: a multiaxial perspective.

Luca Prosperini, Carla Tortorella, Frederik Barkhof, Luca Battistini, Benedetta Bodini, Massimiliano Calabrese, Declan Chard, Olga Ciccarelli, Nicola De Stefano, Christian Enzinger and 16 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Luca ProsperiniMS Centre, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy.ORCID http://orcid.org/0000-0003-3237-6267
Carla TortorellaMS Centre, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy.
Frederik BarkhofUCL Hawkes Institute and UCL Queen Square Institute of Neurology, University College London, London, UK.
Luca BattistiniNeuroimmunology Unit, IRCCS Santa Lucia Foundation, Rome, Italy.
Benedetta BodiniParis Brain Institute, Sorbonne Université, Paris, France.
Massimiliano CalabreseDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Declan ChardQueen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID http://orcid.org/0000-0003-3076-2682
Olga CiccarelliQueen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, UCL, London, UK.ORCID http://orcid.org/0000-0001-7485-1367
Nicola De StefanoDepartment of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Christian EnzingerDepartment of Neurology, Medical University of Graz, Graz, Austria.
Massimo FilippiNeuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ludwig KapposResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0003-4175-5509
Jens KuhleResearch Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-6963-8892
Roberta MagliozziDepartment of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Maria Assunta RoccaNeuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-2358-4320
Alex RoviraSection of Neuroradiology, Department of Radiology (IDI), Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona, Barcelona, Spain.
Serena RuggieriMS Centre, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy.
Jaume Sastre-GarrigaDepartment of Neurology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.
Menno M SchoonheimMS Center Amsterdam, Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-2504-6959
Maria Pia SormaniDepartment of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.ORCID http://orcid.org/0000-0001-6892-104X
Bruno StankoffParis Brain Institute, Sorbonne Université, Paris, France.
Mar TintoréDepartment of Neurology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9999-5359
Tarek YousryQueen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, UCL, London, UK.
Xavier MontalbanDepartment of Neurology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain.
Claudio GasperiniMS Centre, Department of Neurosciences, San Camillo-Forlanini Hospital, Rome, Italy. c.gasperini@libero.it.ORCID http://orcid.org/0000-0002-3959-4067
MAGNIMS network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a condition marked by considerable prognostic uncertainty, despite advances in therapeutic strategies and biomarker development. Current approaches to prognosis are largely focused on disease burden, failing to consider the influence of compensatory mechanisms, which complicate the evaluation of long-term outcomes. No unified framework currently exists to guide the integration of diverse prognostic factors, ranging from lesion burden and location to neuroaxonal injury, structural and cognitive reserve, lifestyle and digital biomarkers. To address this gap, a consortium from the Magnetic Resonance Imaging in MS (MAGNIMS) network has reviewed the latest research on MS prognosis and, in this Expert Recommendation, proposes a multiaxial conceptual model that incorporates the overall burden of damage, the topography of injury and the capacity for compensation. These three axes can be explored with different tools, such as clinical history and neurological examination, MRI-based tools, biofluid markers and additional techniques, including multimodal evoked potentials, optical coherence tomography and technology-based passive monitoring systems. The MAGNIMS consortium evaluated the existing tools, their limitations and potential future directions across each axis, proposing an integrated, non-prescriptive framework for individualized risk prediction. This work is intended not as a clinical guideline but as a conceptual roadmap to inform future research and refinement of prognostic models in MS.

Indexed as

Multiple SclerosisHumansMagnetic Resonance ImagingPrognosis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.